Abstract: The present invention relates to compounds that are fast dissociating dopamine 2 receptor antagonists, processes for preparing these compounds, pharmaceutical compositions comprising these compounds as an active ingredient. The compounds find utility as medicines for treating or preventing central nervous system disorders, for example schizophrenia, by exerting an antipsychotic effect without motor side effects.

Abstract: An integrated antenna package includes an interposer, an integrated circuit die, and a cap that forms a cavity within the integrated antenna package. A lossy EBG structure resides at the cap overlying the integrated circuit device. A lossless EBG structure resides at the cap overlying a microstrip feedline. A radar module includes a plurality of receive portions, each receive portion including a parabolic structure having a reflective surface, an absorber structure, a lens, and an antenna.

Abstract: A supercapacitor desalination cell comprises a first electrode, a second electrode, a spacer disposed between the first and second electrodes, and a monovalent ion selective layer disposed on at least one of the first and second electrodes. A supercapacitor desalination device and a method for desalination of a liquid are further presented.

Abstract: A ventilating sill for elevating a wall partition from a floor surface in order to isolate the wall partition from moisture and humidity that can emanate from the floor surface or be present thereon. The ventilating sill includes a block having a support surface, a base surface, two opposed side surfaces and a plurality of spaced channels extending between the side surfaces forming channeled surfaces. The ventilating sill further includes a pair of slats, each slat extending from each side surface upwardly towards the wall partition at a right angle to the support surface, the slats defining a support area, and being adapted to guide the wall partition onto the support surface and at least one aperture communicating between the support area and an ambient environment for ventilating the support area and draining moisture and humidity therefrom.

Abstract: The present invention relates to compounds that are fast dissociating dopamine 2 receptor antagonists, processes for preparing these compounds, pharmaceutical compositions comprising these compounds as an active ingredient. The compounds find utility as medicines for treating or preventing central nervous system disorders, for example schizophrenia, by exerting an antipsychotic effect without motor side effects.

Abstract: The present invention relates to 4-aryl-6-piperazin-1-yl-3-substituted-pyridazines that are fast dissociating dopamine 2 receptor antagonists, processes for preparing these compounds, pharmaceutical compositions comprising these compounds as an active ingredient. The compounds find utility as medicines for treating or preventing central nervous system disorders, for example schizophrenia, by exerting an antipsychotic effect without motor side effects.

Abstract: An ion exchange polymer is provided. The ion exchange polymer is a reaction product of a reaction between a crosslinker monomer and a cationic monomer. The crosslinker monomer is a reaction product of a reaction between a first crosslinking monomer and a second crosslinking monomer. Further, the cationic monomer comprises a quaternary ammonium group. A method for making an ion exchange polymer is also provided. The method comprises a step of preparing a curable solution and a step of curing the curable solution. The step of preparing the curable solution comprises mixing a pair of crosslinking monomers, a cationic monomer that comprises a quaternary ammonium group and an acid. A membrane is also provided. The membrane comprises the ion exchange polymer made by the method provided.

Abstract: A method for cross-linking a styrenic polymer, the method comprising providing a partly sulphonated styrenic polymer and cross-linking the partly sulphonated styrenic polymer in the presence of a polyphosphoric acid.

Abstract: This invention concerns the use of a compound of formula (I) a N-oxide, a pharmaceutically acceptable addition salt, a quaternary amine and a stereochemically isomeric form thereof, wherein Z is hydrogen, halo, C1-6alkyl, Het1, HO—C1-6alkyl-, cyano-C1-6alkyl-, amino-C(?O)—C1-6alkyl-, formylamino-C1-6alkyl-, C1-6alkyl-C(?O)—NH—C1-6alkyl-, mono- or di(C1-6alkyl)amino-C(?O)—C1-6alkyl-, phenyl-C1-6alkyl-, or Het4-C1-6alkyl-; Q is phenyl, pyridyl, benzofuranyl, 2,3-dihydro-benzofuranyl, pyrazolyl, isoxazolyl or indazolyl wherein each of said ring systems is optionally being substituted with up to three substituents each independently selected from halo, cyano, C1-6alkyl, C1-6alkyl-O—, C1-6alkylthio, Ar or polyhaloC1-6alkyl; L is phenyl, pyridyl, pyrimidazolyl, 8-Azapyrimidazolyl, pyridazinyl, imidazothiazolyl or furanyl wherein each of said ring systems may optionally be substituted with one or two or more substituents, each substituent independently being selected from halo, hydroxy, amino, cyano, C1-6alkyl

Abstract: An integrated antenna package includes an interposer, an integrated circuit die, and a cap that forms a cavity within the integrated antenna package. A lossy ERG structure resides at the cap overlying the integrated circuit device. A lossless EBG structure resides at the cap overlying a microstrip feedline. A radar module includes a plurality of receive portions, each receive portion including a parabolic structure having a reflective surface, an absorber structure, a lens, and an antenna.

Abstract: An integrated and reactive music control system designed for silencing music in an operating room during critical events. The preferred system contains a music input, a hardware interface to integrate real-time patient physiologic data, a software application to process the data, a user interface, and a music output, any portion or all of which may be hardwired or wireless. Through the user interface, medical personnel may adjust pre-set limits on physiologic parameters that indicate abnormality or risk to a particular patient. To reduce ambient noise pollution and permit communication and concentration of the surgical team, volume is reduced as a patient's condition deteriorates. Resulting in additional safety to patients in the operating room, the cessation of music may capture the attention of health care professionals who suffer from alarm desensitization. The system's integration includes an anesthesia monitor, but may extend to include a hospital data server and EMR systems.

Abstract: A compound represented by the general formula (1) is useful as a light emitting material. In the general formula (1), Ar1 to Ar3 represent an aryl group, provided that Ar2 and Ar3 are the same as each other, and at least one of Ar1 to Ar3 represents an aryl group substituted with a group represented by the general formula (2). In the general formula (2), R1 to R8 represent a hydrogen atom or a substituent; Z represents O, S, R9—N, (R10) (R11) C, or (R12) (R13)Si; and R9 to R13 each independently represent a hydrogen atom or a substituent.

Abstract: The present invention relates to novel 5,6-dihydro-2H-[1,4]oxazin-3-ylamine derivatives as inhibitors of beta-secretase, also known as beta-site amyloid cleaving enzyme, BACE, BACE1, Asp2, or memapsin2. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which beta-secretase is involved, such as Alzheimer's disease (AD), mild cognitive impairment, senility, dementia, dementia with Lewy bodies, Down's syndrome, dementia associated with stroke, dementia associated with Parkinson's disease and dementia associated with beta-amyloid.

Abstract: The present invention relates to novel 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5H)-one derivatives as negative allosteric modulators (NAMs) of the metabotropic glutamate receptor subtype 2 (“mGluR2”). The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention or treatment of disorders in which the mGluR2 subtype of metabotropic receptors is involved.

Abstract: An ion exchange membrane and a method of making it. The membrane may be used, for example, in an electrodialysis module or electrochemical cell. The membrane comprises an ion exchange polymer and inorganic particles preferably linked to the ion exchange polymer. To make a membrane, inorganic particles are mixed into an ion exchange membrane pre-cursor. A polymerization initiator or catalyst is then added and the resulting mixture is placed in a form and cured. The inorganic particles may comprise, for example, an oxidized form of graphite such as graphite oxide. The ion exchange polymer may comprise an ionic monomer, containing a quaternary ammonium group for anion exchange or a sulfonate group for cation exchange, along with a crosslinking co-monomer containing polymerizable diacrylic functionalities. The membrane is self-supporting and can be made without a supporting fabric.

Abstract: The present invention relates to methods of treating various central nervous system disorders using novel triazolo[4,3-a]pyridine derivatives of Formula (I) wherein all radicals are as defined in the claims. The compounds according to the invention are positive allosteric modulators of the metabotropic glutamate receptor subtype 2 (“mGluR2”), which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds for the prevention or treatment of neurological and psychiatric disorders and diseases in which mGluR2 is involved.

Abstract: The present invention relates to novel triazolo[4,3-a]pyridine derivatives of Formula (I) wherein all radicals are as defined in the claims. The compounds according to the invention are positive allosteric modulators of the metabotropic glutamate receptor subtype 2 (“mGluR2”), which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds for the prevention or treatment of neurological and psychiatric disorders and diseases in which mGluR2 is involved.

Abstract: The present invention relates to novel compounds, in particular novel pyridinone derivatives according to Formula (I) wherein all radicals are defined in the application and claims. The compounds according to the invention are positive allosteric modulators of metabotropic receptors—subtype 2 (“mGluR2”) which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. In particular, such diseases are central nervous system disorders selected from the group of anxiety, schizophrenia, migraine, depression, and epilepsy. The invention is also directed to pharmaceutical compositions and processes to prepare such compounds and compositions, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR2 is involved.

Abstract: Various of the disclosed embodiments generally contemplate computer-implemented systems and methods for selecting an electronic or virtual gift card from among a plurality of possible gift cards or gift card issuers. Various of the embodiments may match and rank the gift cards according to a gift card recipient's characteristics, and possibly to the electronic or virtual gift card itself. Certain embodiments also contemplate the selection of physical gift cards selection, matching, and ranking aspects of the invention. Various methods for operating a gift card business using certain of the embodiments are also disclosed.

Abstract: The present invention relates to novel triazolo[4,3-a]pyridine derivatives of Formula (I) wherein all radicals are as defined in the claims. The compounds according to the invention are positive allosteric modulators of the metabotropic glutamate receptor subtype 2 (“mGluR2”), which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds for the prevention or treatment of neurological and psychiatric disorders and diseases in which mGluR2 is involved.